Research

Hormonal

SGLT-2 inhibitors reduce the risk of worsening heart failure and cardiovascular death in patients with heart failure with reduced ejection fraction (HFrEF), regardless of diabetes status.

If you have heart failure with a weak pumping heart (HFrEF), SGLT-2 inhibitors (like Jardiance or Farxiga) are now a standard part of treatment. They reduce hospitalizations and death, even if you don't have diabetes. They help your heart pump more efficiently.

StrongSupportsVERY_HIGH confidence
Findings of DAPA-HF were consistent in patients regardless of the presence or absence of T2DM.
Kushner · The Journal of Family Practice · 2021

Why this rating

Based on DAPA-HF and EMPEROR-Reduced trials.

Source

Obesity 2021: Current Clinical Management of a Chronic, Serious Disease

Kushner · The Journal of Family Practice · 2021

DOI 10.12788/jfp.0221

narrative_reviewCited 4×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →